Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018

Sonoma Pharmaceuticals (Nasdaq: SNOA), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced financial results for the third quarter of fiscal year 2018, ended December 31, 2017.

As quoted in the press release:

“This quarter’s revenue of $4.8 million is our highest quarterly revenue in the history of the company.  This record revenue has been driven by robust year-over-year and quarter-over-quarter growth in the prescription dermatology business – our primary focus over the last three years.  These results include sales growth in our Levicyn, Celacyn, Ceramax, SebuDerm and Mondoxyne products,” said Jim Schutz, Sonoma Pharmceuticals CEO.

Click here to read the full press release.